Papers 3359
1 page of 336 pages (3,359 results)
#1Alexander Konnopka (UHH: University of Hamburg)H-Index: 19
#2Hannah König (UHH: University of Hamburg)
Background Anxiety disorders (AD) are common mental disorders, for which several cost-of-illness (COI) studies have been conducted in the past.
#1Paul Tappenden (University of Sheffield)H-Index: 33
#2J. Jaime Caro (LSE: London School of Economics and Political Science)H-Index: 1
#1Eifiona Wood (RMIT: RMIT University)
#2Dyfrig A. Hughes (RMIT: RMIT University)H-Index: 38
#1Margrét V. Bjarnadóttir (UMD: University of Maryland, College Park)H-Index: 3
#2David Anderson (Villanova University)H-Index: 7
Last.Cpt Alan Nelson (Stanford University)H-Index: 4
view all 5 authors...
Background During the period from 1999 to 2016, more than 350,000 Americans died from overdoses related to the use of prescription opioids. To the extent that supply is directly related to overprescribing, policy interventions aimed at changing prescriber behavior, such as the recent Centers for Disease Control and Prevention guideline, are clearly warranted. Although these could plausibly reduce the prevalence of opioid overuse and dependency, little is known about their economic and health-rel...
#1David D. Kim (Tufts Medical Center)H-Index: 11
#2Gregory F. Guzauskas (UW: University of Washington)H-Index: 5
Last.Josh J. Carlson (UW: University of Washington)H-Index: 18
view all 7 authors...
Background Value of information (VOI) analysis often requires modeling to characterize and propagate uncertainty. In collaboration with a cancer clinical trial group, we integrated a VOI approach to assessing trial proposals.
#1Eric Q. Wu (AG: Analysis Group)H-Index: 42
#2Z Zhou (AG: Analysis Group)H-Index: 2
Last.Praveen Thokala (University of Sheffield)H-Index: 16
view all 5 authors...
Economic models are increasingly being used by health economists to assess the value of health technologies and inform healthcare decision making. However, most published economic models represent a kind of black box, with known inputs and outputs but undisclosed internal calculations and assumptions. This lack of transparency makes the evaluation of the model results challenging, complicates comparisons between models, and limits the reproducibility of the models. Here, we aim to provide an ove...
1 CitationsSource
#1Susanne SchmitzH-Index: 9
#2Tatjana T. Makovski (UM: Maastricht University)
Last.Maurice P. Zeegers (PHRI: Public Health Research Institute)H-Index: 50
view all 6 authors...
Background Health-related quality of life (HRQoL) is a key outcome in cost-utility analyses, which are commonly used to inform healthcare decisions. Different instruments exist to evaluate HRQoL, however while some jurisdictions have a preferred system, no gold standard exists. Standard meta-analysis struggles with the variety of outcome measures, which may result in the exclusion of potentially relevant evidence.
#1Matthew Walton (Ebor: University of York)H-Index: 2
#2Sahar Sharif (Ebor: University of York)H-Index: 1
Last.Robert Hodgson (Ebor: University of York)H-Index: 7
view all 5 authors...
As part of the National Institute for Health and Care Excellence’s (NICE’s) Single Technology Appraisal (STA) process, Novartis submitted evidence on the clinical effectiveness and cost-effectiveness of tisagenlecleucel for treating paediatric and young adult patients (under the age of 25 years) with relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (ALL). This article presents a summary of the Evidence Review Group’s (ERG’s) independent review of the evidence submission, the com...
#1Sandjar Djalalov (Westminster International University in Tashkent)
#2J. Beca (Cancer Care Ontario)H-Index: 8
Last.Jeffrey S. Hoch (UC Davis: University of California, Davis)H-Index: 31
view all 4 authors...
Objectives The aim of this study was to use Microsoft Excel spreadsheet software to fit parametric survival distributions. We also explain the differences between individual patient data (IPD) and survival data reconstructed in Excel and SAS.
#1Elizabeth Brouwer (UW: University of Washington)H-Index: 6
#2Anirban Basu (UW: University of Washington)H-Index: 34
Last.Kai Yeung (KP: Kaiser Permanente)
view all 3 authors...
Background and Objective It is unclear whether private insurance benefit designs align with the most widely used ex-US definition of value, the incremental cost-effectiveness ratio (ICER). A large Pacific Northwest private insurance plan explicitly implemented a tiered formulary based on cost-effectiveness estimates of individual drugs in 2010, resulting in cost savings to the plan without negatively affecting patient health service utilization. Given the pressures of rising costs, we investigat...
Top fields of study
Health care
Intensive care medicine
Physical therapy